OncoIndustry
Natera and Kupando Therapeutics Collaborate on Phase 1 Trial of KUP-101 in Advanced Skin Cancers
Natera and Kupando Therapeutics

Natera and Kupando Therapeutics Collaborate on Phase 1 Trial of KUP-101 in Advanced Skin Cancers

Natera, shared on LinkedIn:

“Natera is collaborating with Kupando Therapeutics to support its Phase 1 trial of KUP-101, an investigational immunotherapy for patients with advanced skin cancers. KUP-101 is designed to activate the innate immune system and induce trained immunity.

Our Latitude™ tissue-free assay will assess serial ctDNA dynamics as part of treatment response monitoring, providing molecular insights to support the clinical development of this promising therapeutic approach. Together with Kupando, we are committed to helping patients with difficult-to-treat cancers.

Read the full press release.”

Other articles about Skin Cancer on OncoDaily.

biomarker testing cancer cancer therapy cancer treatment esophageal cancer esophageal cancer treatment gastric cancer gastric cancer treatment gastroesophageal adenocarcinoma gastroesophageal cancer gastrointestinal cancer Gastrointestinal Oncology GEA GI oncology HER2 HER2 Biomarker HER2 expression HER2 positive cancer HER2 protein HER2 Testing HER2-Directed Therapy HER2-targeted therapies Jazz Pharmaceuticals OncoDaily Oncology Precision Medicine Precision Oncology targeted cancer therapy targeted therapy